Event Title

P-11 Novel Heterocyclic Arylidene Derivatives as Anticancer Agents against U87 Human Glioblastoma Cells

Presenter Information

Benjamin Hiramoto

Start Date

2-28-2020 2:30 PM

Description

The primary objective of this research study was to investigate the efficacy of novel hybrid heterocyclic arylidenes as anticancer agents against the proliferation and invasiveness of glioblastoma cancer cells. A group of novel heterocyclic arylidenes were produced from a set of aryl aldehydes and rhodanine acetic acid in a pancreatin-catalyzed controlled reflux reaction. These compounds were subsequently administered to U87 glioblastoma cancer cells at different concentrations in a 12-well cell viability assay to determine each compound’s LC50. Compounds showed various levels of efficacy and were dependent upon the substituent composition.

Acknowledgments

J.N. Andrews Honors Scholar

Mentors:

Denise Smith, Biology

Desmond H. Murray, Chemistry & Biochemistry

This document is currently not available here.

Share

COinS
 
Feb 28th, 2:30 PM

P-11 Novel Heterocyclic Arylidene Derivatives as Anticancer Agents against U87 Human Glioblastoma Cells

The primary objective of this research study was to investigate the efficacy of novel hybrid heterocyclic arylidenes as anticancer agents against the proliferation and invasiveness of glioblastoma cancer cells. A group of novel heterocyclic arylidenes were produced from a set of aryl aldehydes and rhodanine acetic acid in a pancreatin-catalyzed controlled reflux reaction. These compounds were subsequently administered to U87 glioblastoma cancer cells at different concentrations in a 12-well cell viability assay to determine each compound’s LC50. Compounds showed various levels of efficacy and were dependent upon the substituent composition.